Defence Therapeutics Appoints Dr. Elias Theodorou as COO to Boost US Market Presence

The latest update is out from Defence Therapeutics ( (TSE:DTC) ).

Defence Therapeutics has appointed Dr. Elias Theodorou as Chief Operating Officer, marking a significant milestone for the company. Dr. Theodorou, a molecular biologist with extensive experience in cancer research and gene delivery, will be based in Boston and is expected to accelerate Defence’s development programs and strengthen its position in the US market. His expertise aligns with Defence’s mission to advance its Accum® technology, potentially catalyzing the company’s platform in the fields of ADCs and radioimmunoconjugates. The appointment is seen as a strategic move to leverage the US biotech ecosystem and forge partnerships that could drive the next wave of cancer therapeutics.

More about Defence Therapeutics

Defence Therapeutics is a publicly-traded clinical-stage biotechnology company focused on developing radio-immuno-conjugate and antibody-drug conjugate (ADC) products using its proprietary ACCUM® technology platform. The company also works on novel immune-oncology vaccines aimed at increasing efficacy and potency against cancer and infectious diseases.

YTD Price Performance: 155.38%

Average Trading Volume: 18,635

Technical Sentiment Signal: Hold

Current Market Cap: $41.02M

For a thorough assessment of DTC stock, go to TipRanks’ Stock Analysis page.